HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
NCT07137637
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
Interventions
DRUG:
HPB-092 tablet
Sponsor
Hangzhou Polymed Biopharmaceuticals, Inc.